Immunogenicity of Inactivated Varicella Zoster Vaccine (ZVIN) in Autologous Hematopoietic Stem Cell Transplant (auto-HSCT) Recipients
نویسندگان
چکیده
1818. Immunogenicity of Inactivated Varicella Zoster Vaccine (ZVIN) in Autologous Hematopoietic Stem Cell Transplant (auto-HSCT) Recipients Michael Boeckh, MD, FIDSA; Ann Arvin, MD, FIDSA, FPIDS; Kathleen Mullane, DO, FIDSA; Drew J. Winston, MD; Janice (Wes) Brown, MD; Steven Pergam, MD, MPH, FIDSA; Kimberly Hurtado, BS; Lei Pang, PhD; Ingi Lee, MD, MSCE; Zoran Popmihajlov, MD, MS and on behalf of the V212 Protocol 001 Study Team; Fred Hutchinson Cancer Research Center, Seattle, Washington; Division of ID/ Department of Ped, Stanford University School of Medicine, Stanford, California; Medicine, University of Chicago Medicine, Chicago, Illinois; University of California at Los Angeles Medical Center, Los Angeles, California; Division of Blood and Marrow Transplant and Division of Infectious Diseases, Department of Medicine, Stanford University School of Medicine, Stanford, California; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, Washington; Merck & Co., Inc., Kenilworth, New Jersey; Merck & Co., Inc., North Wales, Pennsylvania
منابع مشابه
Vaccine effectiveness against influenza-associated hospitalization among children aged < 13 years using a hospital-based surveillance system in Minnesota, 2013 – 2016
1818. Immunogenicity of Inactivated Varicella Zoster Vaccine (ZVIN) in Autologous Hematopoietic Stem Cell Transplant (auto-HSCT) Recipients Michael Boeckh, MD, FIDSA; Ann Arvin, MD, FIDSA, FPIDS; Kathleen Mullane, DO, FIDSA; Drew J. Winston, MD; Janice (Wes) Brown, MD; Steven Pergam, MD, MPH, FIDSA; Kimberly Hurtado, BS; Lei Pang, PhD; Ingi Lee, MD, MSCE; Zoran Popmihajlov, MD, MS and on behalf...
متن کاملLive attenuated varicella-zoster vaccine in hematopoietic stem cell transplantation recipients.
Hematopoietic stem cell transplantation (HSCT) recipients are at risk for varicella-zoster virus (VZV) reactivation. Vaccination may help restore VZV immunity; however, the available live attenuated VZV vaccine (Zostavax) is contraindicated in immunocompromised hosts. We report our experience with using a single dose of VZV vaccine in 110 adult autologous and allogeneic HSCT recipients who were...
متن کاملFatal visceral varicella-zoster developing early after autologous hematopoietic stem cell transplantation for refractory diffuse large B-cell lymphoma.
A middle-aged woman who had undergone autologous hematopoietic stem cell transplantation (HSCT) 1 month previously suffered severe epigastralgia and relapse of lymphoma. The epigastralgia was not relieved by chemotherapy. Thereafter, her pancreatic and hepatic enzyme levels were markedly elevated and disseminated varicella emerged. Despite acyclovir administration, her general condition deterio...
متن کاملInduction of Cytomegalovirus-Specific T Cell Responses in Healthy Volunteers and Allogeneic Stem Cell Recipients Using Vaccination With Messenger RNA–Transfected Dendritic Cells
BACKGROUND Infection with human cytomegalovirus (CMV) is a significant cause of morbidity and mortality in solid organ and hematopoietic stem cell transplant (HSCT) recipients. METHODS The present study explored the safety, feasibility, and immunogenicity of CMV pp65 messenger RNA-loaded autologous monocyte-derived dendritic cells (DC) as a cellular vaccine for active immunization in healthy ...
متن کاملSafety and immunogenicity of modified vaccinia Ankara in hematopoietic stem cell transplant recipients: a randomized, controlled trial.
BACKGROUND Modified vaccinia Ankara (MVA-BN, IMVAMUNE) is emerging as a primary immunogen and as a delivery system to treat or prevent a wide range of diseases. Defining the safety and immunogenicity of MVA-BN in key populations is therefore important. METHODS We performed a dose-escalation study of MVA-BN administered subcutaneously in 2 doses, one on day 0 and another on day 28. Twenty-four...
متن کامل